Re: Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial

We read with great interest the article entitled ‘Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial’ recently published in the European Journal of Cancer (May 2022) by Shi and colleagues [1]. This single-centre, open-labelled, randomised controlled trial (RCT) initially included 236 patients with hepatocellular carcinoma (HCC) who underwent marginal liver resection (distance from tumour to resection margin ≤ 1 mm) [2], and screened 76 HCC patients with microvascular invasion (MVI) using stringent criteria thereafter.

Lascia un commento